- Home
- Automated
- List of product information
- LASIX TABLET 40 MG [SIN00199P]
LASIX TABLET 40 MG [SIN00199P]
Active ingredients: LASIX TABLET 40 MG
Product Info
LASIX TABLET 40 MG
[SIN00199P]
Product information
Active Ingredient and Strength | FUROSEMIDE - 40 MG |
Dosage Form | TABLET |
Manufacturer and Country | OPELLA HEALTHCARE INTERNATIONAL SAS - FRANCE |
Registration Number | SIN00199P |
Licence Holder | SANOFI-AVENTIS SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C03CA01 |
Indications
Oedema due to cardiac, hepatic, or renal disorders (in the presence of nephrotic syndrome, treatment of the basic disorder is the prime concern). Oedema due to burns. Mild to moderate hypertension.
Dosage
In general, the dose used must be the lowest which is sufficient to achieve the desired effect.
Unless otherwise prescribed, the following dosage guidelines apply:
In adults, treatment is usually started with 1/2–1–2 tablets daily; the maintenance dose is 1/2– 1 tablet daily.
In infants and children, Lasix should in principle be administered orally. The dosage recommendation is 2 mg furosemide per kg body weight up to a daily maximum of 40 mg.
Parenteral administration (if necessary, continuous drip infusion) is indicated only in life-threatening conditions.
Contraindications
Lasix must not be used in patients with:
hypersensitivity to furosemide, sulfonamides (possible cross sensitivity with furosemide) or to any of the excipients
renal failure with anuria refractory to furosemide therapy
hepatic coma and precoma associated with hepatic encephalopathy
severe hypokalaemia – see Adverse Reaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information
severe hyponatraemia
decreased volume of blood in the body (hypovolaemia) – with or without reduced blood pressure (hypotension) – or dehydration
breast-feeding mothers
